Increased erythropoietin elimination in fetal sheep following chronic phlebotomy

Pharmaceutical Research

Volumn 24, Issue 9, 2007, Pages 1653-1659

  Freise, Kevin J ^a   Widness, John A ^b   Segar, Jeffrey L ^b   Schmidt, Robert L ^b   Veng Pedersen, Peter ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Developmental comparison; Erythropoietin receptors; Fetus; Pharmacokinetics; Receptor regulation

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; TRACER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ELIMINATION; FEMALE; FETUS; MATHEMATICAL MODEL; MICHAELIS CONSTANT; NONHUMAN; PHLEBOTOMY; PRIORITY JOURNAL; SHEEP;

ANEMIA; ANIMALS; ANIMALS, NEWBORN; ERYTHROPOIETIN; FEMALE; FETUS; PHLEBOTOMY; PREGNANCY; RECEPTORS, ERYTHROPOIETIN; SHEEP;

EID: 34547613348     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9295-3     Document Type: Article

References (47)

1. R. Hoffman, E. J. Benz Jr., S. J. Shattil, B. Furie, H. J. Cohen, L. E. Silberstein, and P. McGlave. Hematology: Basic Principles and Applications, Elsevier, USA, 2005.
2. J. W. Fisher. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (Maywood) 228:1-14 (2003).
3. J. Rossert and K. U. Eckardt. Erythropoietin receptors: their role beyond erythropoiesis. Nephrol. Dial. Transplant. 20:1025-1028 (2005).
4. M. Brines and A. Cerami. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int. 70:246-250 (2006).
5. K. Sawada, S. B. Krantz, C. H. Dai, S. T. Koury, S. T. Horn, A. D. Glick, and C. I. Civin. Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors. J. Cell Physiol. 142:219-230 (1990).
6. J. W. Adamson. Regulation of red blood cell production. Am. J. Med. 101:4S-6S (1996).
7. J. H. Jandl. Blood: Textbook of Hematology, Little Brown, USA, 1996.
8. S. T. Sawyer, S. B. Krantz, and E. Goldwasser. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J. Biol. Chem. 262:5554-62 (1987).
9. D. L. Beckman, L. L. Lin, M. E. Quinones, and G. D. Longmore. Activation of the erythropoietin receptor is not required for internalization of bound erythropoietin. Blood 94:2667-75 (1999).
10. S. T. Sawyer and W. D. Hankins. The functional form of the erythropoietin receptor is a 78-kDa protein: correlation with cell surface expression, endocytosis, and phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 90:6849-6853 (1993).
11. M. Kato, H. Kamiyama, A. Okazaki, K. Kumaki, Y. Kato, and Y. Sugiyama. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J. Pharmacol. Exp. Ther. 283:520-527 (1997).
12. W. Jelkmann. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur. J. Haematol. 69:265-274 (2002).
13. M. Kato, Y. Kato, and Y. Sugiyama. Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. Am. J. Physiol. 276:E887-E895 (1999).
14. H. Kinoshita, N. Ohishi, S. Tokura, and A. Okazaki. Pharmacokinetics and distribution of recombinant human erythropoietin in rats with renal dysfunction. Arzneim-Forsch/Drug Res. 42(I):682-686 (1992).
15. J. A. Widness, P. Veng-Pedersen, C. Peters, L. M. Periera, R. L. Schmidt, and L. S. Lowe. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J. Appl. Physiol. 80:140-148 (1996).
16. T. Sans, J. Joven, E. Vilella, G. Masdeu, and M. Farre. Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusion. Clin. Exp. Pharmacol. Physiol. 27:179-184 (2000).
17. P. Veng-Pedersen, S. Chapel, N. H. Al-Huniti, R. L. Schmidt, E. M. Sedars, R. J. Hohl, and J. A. Widness. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm. Drug Dispos. 25:149-156 (2004).
18. S. H. Chapel, P. Veng-Pedersen, R. L. Schmidt, and J. A. Widness. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp. Hematol. 29:425-431 (2001).
19. S. Chapel, P. Veng-Pedersen, R. J. Hohl, R. L. Schmidt, E. M. McGuire, and J. A. Widness. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J. Pharmacol. Exp. Ther. 298:820-824 (2001).
20. P. Veng-Pedersen, S. Chapel, N. H. Al-Huniti, R. L. Schmidt, E. M. Sedars, R. J. Hohl, and J. A. Widness. A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep. J. Pharmacol. Exp. Ther. 306: 532-537 (2003).
21. M. Cazzola, R. Guarnone, P. Cerani, E. Centenara, A. Rovati, and Y. Beguin. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 91:2139-2145 (1998).
22. Y. Beguin, G. K. Clemons, P. Pootrakul, and G. Fillet. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81:1067-1076 (1993).
23. G. de Klerk, P. C. Rosengarten, R. J. Vet, and R. Goudsmit. Serum erythropoietin (EST) titers in anemia. Blood 58:1164-1170 (1981).
24. S. E. Juul, A. T. Yachnis, and R. D. Christensen. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. 52:235-249 (1998).
25. F. Farrell and A. Lee. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 9(Suppl. 5):18-30 (2004).
26. J. A. Widness, P. Veng-Pedersen, N. B. Modi, R. L. Schmidt, and D. H. Chestnut. Developmental differences in erythropoietin pharmacokinetics: Increased clearance and distribution in fetal and neonatal sheep. J. Pharmacol. Exp. Ther. 261:977-984 (1992).
27. M. S. Brown, M. A. Jones, R. K. Ohls, and R. D. Christensen. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J. Pediatr. 122:655-657 (1993).
28. P. Veng-Pedersen, J. A. Widness, J. Wang, and R. L. Schmidt. A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination. J. Pharmacokinet. Biopharm. 25:569-593 (1997).
29. R. Ramakrishnan, W. K. Cheung, M. C. Wacholtz, N. Minton, and W. J. Jusko. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J. Clin. Pharmacol. 44:991-1002 (2004).
30. P. Veng-Pedersen, J. A. Widness, L. M. Pereira, R. L. Schmidt, and L. S. Lowe. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm. Drug Dispos. 20:217-223 (1999).
31. P. Veng-Pedersen, J. A. Widness, L. M. Pereira, C. Peters, R. L. Schmidt, and L. S. Lowe. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J. Pharm. Sci. 84:760-767 (1995).
32. J. J. Jennings and J. P. Crowley. The influence of mating management on fertility in ewes following progesterone-PMS treatment. Vet. Rec. 90:495-498 (1972).
33. J. L. Segar, K. Bedell, W. V. Page, J. E. Mazursky, A. M. Nuyt, and J. E. Robillard. Effect of cortisol on gene expression of the renin-angiotensin system in fetal sheep. Pediatr. Res. 37:741-746 (1995).
34. J. A. Widness, R. L. Schmidt, P. Veng-Pedersen, N. B. Modi, and S. T. Sawyer. A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies. J. Lab. Clin. Med. 119:285-294 (1992).
35. M. F. Hutchinson, and F. R. deHoog. Smoothing noise data with spline functions. Numer. Math. 47:99-106 (1985).
36. H. Akaike. Automatic control: A new look at the statistical model identification. IEEE Trans. 19:716-723 (1974).
37. P. Veng-Pedersen. Curve fitting and modelling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J. Pharmacokinet. Biopharm. 5:513-531 (1977).
38. S. H. Chapel, P. Veng-Pedersen, R. L. Schmidt, and J. A. Widness. A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J. Pharmacol. Exp. Ther. 295:346-351 (2000).
39. P. Veng-Pedersen, S. Chapel, R. L. Schmidt, N. H. Al-Huniti, R. T. Cook, and J. A. Widness. An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia. Pharm. Res. 19:1630-1635 (2002).
40. N. H. Al-Huniti, J. A. Widness, R. L. Schmidt, and P. Veng-Pedersen. Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis. J. Pharmacokinet. Pharmacodyn. 32:359-376 (2005).
41. R. A. Brace. Blood volume and its measurement in the chronically catheterized sheep fetus. Am. J. Physiol. 244: H487-H494 (1983).
42. A. C. Guyton, and J. E. Hall. Textbook of Medical Physiology, Saunders, Philadelphia, 2000.
43. R. S. Hillman, K. A. Ault, and H. M. Rinder. Hematology in Clinical Practice, McGraw-Hill, USA, 2005.
44. R. V. Pierre. Reticulocytes. Their usefulness and measurement in peripheral blood. Clin. Lab. Med. 22:63-79 (2002).
45. C. Brugnara. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders. Int. J. Clin. Lab. Res. 28:1-11 (1998).
46. A. Major, C. Bauer, C. Breymann, A. Huch, and R. Huch. rh-erythropoietin stimulates immature reticulocyte release in man. Br. J. Haematol. 87:605-608 (1994).
47. J. K. Chamberlain, L. Weiss, and R. I. Weed. Bone marrow sinus cell packing: a determinant of cell release. Blood. 46:91-102 (1975).